Can the use of iron phthalocyanine-derivative mouthrinses in COVID-19 patients provide systemic benefits? Research into this potential should be considered.

Aim: The purpose of this brief report is to discuss the impact of an oral rinse and spray containing an iron phthalocyanine derivative as an additional therapy in hospitalized COVID-19 patients.

Methods: In the first study by this group of authors published on this topic, the clinical status of 22 patients with COVID-19 who were hospitalized and receiving PDMS (phthalocyanine derivative mouth spray) was assessed using the Karnofsky scale (KS) for thtree days (D0, D2, and D4). In another study, the laboratory data (CBC, D-dimer, Ferritin, and C-reactive protein [CRP]) of 41 patients hospitalized with COVID-19 who took part in a randomized clinical trial with an MIPD (mouthwash with iron phthalocyanine derivative) were evaluated retrospectively on the first day of intervention (D1) and 48 hours later (D2).